Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy

References

• al Dieri R, Alban S, Béguin S, Hemker HC. 2004. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. Journal of Thrombosis and Haemostasis 2:1395–1401.
   PubMed Web of Science ®Google Scholar
• Alexandersson M, Mellström D, Hellgren M. 2001. Bone density after long term thromboprophylaxis or treatment with dalteparin (Fragmin) during pregnancy [abstract]. 18th International Society on Thrombosis and Haemostasis, 2001 Jul 6–12; Paris, France.
   Google Scholar
• Ananth CV, Keyes KM, Hamilton A, Gissler M, Wu C, Liu S, et al. 2015. An international contrast of rates of placental abruption: an age-period-cohort analysis. PLoS One 10:e0125246.
   PubMed Web of Science ®Google Scholar
• Antman EM. 2001. The search for replacements for unfractionated heparin. Circulation 103:2310–2314.
   PubMed Web of Science ®Google Scholar
• Antovic A, Blombäck M, Bremme K, He S. 2002. The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism. Blood Coagulation & Fibrinolysis. 13:181–186.
   PubMed Web of Science ®Google Scholar
• Badaracco MA, Vessey MP. 1974. Recurrence of venous thromboembolic disease and use of oral contraceptives. British Medical Journal 1:215–217.
   PubMedGoogle Scholar
• Barbour LA, Oja JL, Schultz LK. 2004. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. American Journal of Obstetrics and Gynecology 191:1024–1029.
   PubMed Web of Science ®Google Scholar
• Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. 2012. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e691S–e736S.
   PubMed Web of Science ®Google Scholar
• Bates SM, Middeldorp S, Rodger M, James AH, Greer I. 2016. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. Journal of Thrombosis and Thrombolysis 41:92–128.
   PubMed Web of Science ®Google Scholar
• Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, et al. 2007. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thrombosis and Haemostasis 98:1237–1245.
   PubMed Web of Science ®Google Scholar
• Björgvinsdottir A, Sporrong T, Hagman A, Hellgren M. 2013. Obstetric thromboprophylaxis in women with high to very-high risk for venous thromboembolism during pregnancy [abstract]. Thrombosis Research S87–S88.
   Web of Science ®Google Scholar
• Blombäck M, Bremme K, Hellgren M, Siegbahn A, Lindberg H. 1998. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy – a longitudinal safety study. Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9:1–9.
   PubMed Web of Science ®Google Scholar
• Boban A, Paulus S, Lambert C, Hermans C. 2017. The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: a retrospective study. Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis 28:199–204.
   PubMed Web of Science ®Google Scholar
• Bombeli T, Raddatz Mueller P, Fehr J. 2001. Evaluation of an optimal dose of low-molecular-weight heparin for thromboprophylaxis in pregnant women at risk of thrombosis using coagulation activation markers. Haemostasis 31:90–98.
   PubMedGoogle Scholar
• Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. 2000. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in This pregnancy study group. New England Journal of Medicine 343:1439–1444.
   PubMed Web of Science ®Google Scholar
• Chunilal SD, Bates SM. 2009. Venous thromboembolism in pregnancy: diagnosis, management and prevention. Thrombosis and Haemostasis 101:428–438.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Martinelli I, Rossi E, Battaglioli T, Za T, Mannuccio Mannucci P, et al. 2006. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. British Journal of Haematology 135:386–391.
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium (eMC). 2016. Fragmin 5000 IU [summary of product characteristics]. Sandwich, UK: Pfizer Limited; [cited 2016 Aug 19]. Available from: https://www.medicines.org.uk/emc/medicine/26896.
   Google Scholar
• Gándara E, Carrier M, Rodger MA. 2014. Intermediate doses of low-molecular-weight heparin for the long-term treatment of pregnancy thromboembolism. A systematic review. Thrombosis and Haemostasis 111:559–561.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elamy I. 2007. Effect of the anti-factorXa and anti-factor IIa activities of low-molecular-weight-heparins upon the phases thrombin generation. Journal of Thrombosis and Haemostasis 5:955–962.
   PubMed Web of Science ®Google Scholar
• Greer IA, Nelson-Piercy C. 2005. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106:401–407.
   PubMed Web of Science ®Google Scholar
• Harris LF, Castro-López V, Jenkins PV, O'Donnell JS, Killard AJ. 2011. Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas. Thrombosis Research 128:e125–e129.
   PubMed Web of Science ®Google Scholar
• Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ. 2005. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Annals of Internal Medicine 143:697–706.
   PubMed Web of Science ®Google Scholar
• Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N, et al. 1997. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thrombosis and Haemostasis 77:39–43.
   PubMed Web of Science ®Google Scholar
• Jacobsen AF, Qvigstad E, Sandset PM. 2003. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. British Journal of Obstetrics and Gynaecology 110:139–144.
   Google Scholar
• Jacobsen AF, Skjeldestad FE, Sandset PM. 2008a. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. Journal of Thrombosis and Haemostasis 6:905–912.
   PubMed Web of Science ®Google Scholar
• Jacobsen AF, Skjeldestad FE, Sandset PM. 2008b. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium – a register-based case-control study. American Journal of Obstetrics and Gynecology 198: 233.e1237.
   Web of Science ®Google Scholar
• James A. Committee on Practice Bulletins—Obstetrics. 2011. Practice bulletin no. 123: thromboembolism in pregnancy. Obstetrics and Gynecology 118:718–729.
   PubMed Web of Science ®Google Scholar
• James AH, Bates SM, Bauer KA, Branch W, Mann K, Paidas M, et al. 2017. Management of hereditary antithrombin deficiency in pregnancy. Thrombosis Research 157:41–45.
   PubMed Web of Science ®Google Scholar
• James AH, Jamison MG, Brancazio LR, Myers ER. 2006. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. American Journal of Obstetrics and Gynecology 194:1311–1315.
   PubMed Web of Science ®Google Scholar
• Johnston JA, Brill-Edwards P, Ginsberg JS, Pauker SG, Eckman MH. 2005. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism. The American Journal of Medicine 118:503–514.
   PubMed Web of Science ®Google Scholar
• Knight M. UKOSS. 2008. Antenatal pulmonary embolism: risk factors, management and outcomes. British Journal of Obstetrics and Gynaecology 115:453–461.
   Google Scholar
• Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, et al. 2001. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. British Journal of Obstetrics and Gynaecology 108:1134–1140.
   Google Scholar
• Lindqvist P, Dahlbäck B, Marŝál K. 1999. Thrombotic risk during pregnancy: a population study. Obstetrics and Gynecology 94:595–599.
   PubMed Web of Science ®Google Scholar
• Lindqvist PG, Bremme K, Hellgren M. Working Group on Hemostatic Disorders (Hem-ARG), Swedish Society of Obstetrics and Gynecology. 2011. Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism. Acta Obstetricia et Gynecologica Scandinavica 90:648–653.
   PubMed Web of Science ®Google Scholar
• Lindqvist PG, Torsson J, Almqvist A, Björgell O. 2008. Postpartum thromboembolism: severe events might be preventable using a new risk score model. Vascular Health and Risk Management 4:1081–1087.
   PubMedGoogle Scholar
• Marik PE, Plante LA. 2008. Venous thromboembolic disease and pregnancy. The New England Journal of Medicine 359:2025–2033.
   PubMed Web of Science ®Google Scholar
• McDonnell BP, Glennon K, McTiernan A, O’Connor HD, Kirkham C, Kevane B, et al. 2017. Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism. Journal of Thrombosis and Thrombolysis 43:105–111.
   PubMed Web of Science ®Google Scholar
• Nelson-Piercy C, Powrie R, Borg JY, Rodger M, Talbot DJ, Stinson J, et al. 2011. Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. European Journal of Obstetrics, Gynecology, and Reproductive Biology 159:293–299.
   PubMed Web of Science ®Google Scholar
• Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C, et al. 2005. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. Journal of Thrombosis Haemostasis 3:949–954.
   PubMed Web of Science ®Google Scholar
• Pettilä V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. 1999. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research 96:275–282.
   PubMed Web of Science ®Google Scholar
• Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. 2008. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. Journal of Thrombosis and Haemostasis 6:632–637.
   PubMed Web of Science ®Google Scholar
• Revelj M, Hagman A, Hellgren M. 2015. Recurrence of VTE, obstetric and neonatal outcomes in 78 women with venous thromboembolism during pregnancy and puerperium [abstract]. 6th International Symposium on Women's Health Issues in Thrombosis, 2015 Feb 13–15; Berlin, Germany.
   Google Scholar
• Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, et al. 2014. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 384:1673–1683.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Kahn SR, Cranney A, Hodsman A, Kovacs MJ, Clement AM, et al. 2007. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis 5:1600–1606.
   PubMed Web of Science ®Google Scholar
• Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S, et al. 2013. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. Journal of Thrombosis and Haemostasis 11:270–281.
   PubMed Web of Science ®Google Scholar
• Rova K, Passmark H, Lindqvist PG. 2012. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertility and Sterility 97:95–100.
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists. 2015. Reducing the risk of venous thromboembolism during pregnancy and the puerperium, Green-top Guideline No. 37a. London, UK: Royal College of Obstetricians and Gynaecologists; [cited 2016 Aug 31]. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
   Google Scholar
• Royal College of Obstetricians and Gynaecologists. 2015. Thromboembolic disease in pregnancy and the puerperium: acute management, Green-top Guideline No. 37b. London, UK: Royal College of Obstetricians and Gynaecologists; [cited 2016 Aug 31]. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37b.pdf
   Google Scholar
• Sanz-Salvador L, García-Pérez MÁ, Tarín JJ, Cano A. 2015. Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture. European Journal of Endocrinology/European Federation of Endocrine Societies 172:R53–R65.
   PubMed Web of Science ®Google Scholar
• Schambeck CM, Eberl E, Geisen U, Grossmann R, Keller F. 2001. The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. Thrombosis and Haemostasis 85:782–786.
   PubMed Web of Science ®Google Scholar
• Schoenbeck D, Nicolle A, Newbegin K, Hanley J, Loughney AD. 2011. The use of a scoring system to guide thromboprophylaxis in a high-risk pregnant population. Thrombosis 2011:652796.
   PubMedGoogle Scholar
• Schultinge L, Knol HM, Kluin-Nelemans HC, Erwich JJ, Meijer K. 2013. Incidence of hypersensitivity skin reactions in patients on full-dose low-molecular-weight heparins during pregnancy. The Netherlands Journal of Medicine 71:518–522.
   PubMed Web of Science ®Google Scholar
• Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, et al. 2003. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstetrics and Gynecology 101:1307–1311.
   PubMed Web of Science ®Google Scholar
• Simeone R, Giacomello R, Bruno G, Parco S, Maximova N, Martinelli M, et al. 2017. Thrombogenesis in thrombophilic pregnancy: evaluation of low-molecular-weight heparin prophylaxis. Acta Haematologica 137:201–206.
   PubMed Web of Science ®Google Scholar
• Swedish Agency for Health Technology Assessment and Assessment of Social Services. 2017. Stockholm, Sweden; [cited 2017 Dec 7]. Available from: http://www.sbu.se/en/About-SBU/
   Google Scholar
• Swedish Society of Obstetrics and Gynecology (SFOG), Working Group on Hemostatic Disorders (Hem-ARG). 2012. Hemostasrubbningar inom obstetrik och gynekologi [Nr 68]. Olovsson M, editor. Stockholm, Sweden. SFOG.
   Google Scholar
• Tengborn L, Bergqvist D, Matzsch T, Bergqvist A, Hedner U. 1989. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?. American Journal of Obstetrics and Gynecology 160:90–94.
   PubMed Web of Science ®Google Scholar
• Townsley DM. 2013. Hematologic complications of pregnancy. Seminars in Hematology 50:222–231.
   PubMed Web of Science ®Google Scholar
• Ulander VM, Stenqvist P, Kaaja R. 2002. Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy. Thrombosis Research 106:13–17.
   PubMed Web of Science ®Google Scholar
• Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ. British Society for Haematology Obstetric Haematology Group. 2007. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. British Journal of Haematology 139:545–558.
   PubMed Web of Science ®Google Scholar
• Wahlberg TB, Kher A. 1994. Low molecular weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 European clinics. Haemostasis 24:55–56.
   PubMedGoogle Scholar
• Wütschert R, Piletta P, Bounameaux H. 1999. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention. Drug Safety 20:515–525.
   PubMed Web of Science ®Google Scholar